Search Result

Results for "

muscle loss

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adrenergic Receptor (3) Androgen Receptor (1) Antibody-Oligonucleotide Conjugates (AOCs) (1) Biochemical Assay Reagents (1) Caspase (2) Ceramidase (1) Cytochrome P450 (1) Drug Isomer (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Integrin (1) Interleukin Related (3) Isotope-Labeled Compounds (1) Melanocortin Receptor (1) nAChR (2) NF-κB (1) NOD-like Receptor (NLR) (2) P2X Receptor (2) Prostaglandin Receptor (2) Reference Standards (1) TGF-β Receptor (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (4) Inflammation/Immunology (5) Metabolic Disease (10) Neurological Disease (6)
Oligonucleotides:	siRNAs (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99355

Bimagrumab 3 Publications Verification Anti-ACVR2B Reference Antibody; BYM338	TGF-β Receptor	Metabolic Disease
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with K_Ds of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .

HY-170794

ALT-007	Acyltransferase Ceramidase	Metabolic Disease
ALT-007 is an orally active serine palmitoyltransferase (SPT) inhibitor that selectively reduces the levels of toxic very-long-chain deoxysphingolipids to enhance protein homeostasis. ALT-007 restores aging-related loss of muscle mass in a mouse model of sarcopenia. ALT-007 enhances protein homeostasis in both mouse and C. elegans models of aging and disease. ALT-007 can be used for age-related neuromuscular diseases research .

HY-19307

SB-273005	Integrin Interleukin Related	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with K_i values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. .

HY-N1993

5-Methyl-7-methoxyisoflavone 3 Publications Verification	Cytochrome P450 NF-κB	Metabolic Disease Cancer
5-Methyl-7-methoxyisoflavone is an orally active anti-oxidant with remyelinating activity. 5-Methyl-7-methoxyisoflavone inhibits the enzyme aromatase, interfering with the normal metabolic pathways of testosterone. 5-Methyl-7-methoxyisoflavone is a non-steroidal anabolic isoflavone, used as a anabolic agent. 5-Methyl-7-methoxyisoflavone shows better potency increasing muscle mass and endurance than Ipriflavone (HY-N0094). 5-Methyl-7-methoxyisoflavone can be used for fat loss besides the maintenance of low cholesterol level and strengthen bones. 5-Methyl-7-methoxyisoflavone is the inhibitor for NF-κB .

HY-164027

MyoMed 205	E1/E2/E3 Enzyme	Metabolic Disease Cancer
MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction .

HY-18102

GLPG0492 Maximum Cited Publications 7 Publications Verification	Androgen Receptor	Neurological Disease
GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

HY-150270A

NP-1815-PX sodium	P2X Receptor Prostaglandin Receptor NOD-like Receptor (NLR) Caspase Interleukin Related	Inflammation/Immunology
NP-1815-PX sodium is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC₅₀ of 0.26 μM against human P2X4 receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis) .

HY-30215

(S)-Leucic acid	Endogenous Metabolite	Metabolic Disease Endocrinology
(S)-Leucic acid is a metabolite of Leucine. (S)-Leucic acid has anabolic effects, particularly promoting muscle protein synthesis. (S)-Leucic acid can be used in the diagnosis of pregnancy loss .

HY-30215R

(S)-Leucic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease Endocrinology
(S)-Leucic acid (Standard) is the analytical standard of (S)-Leucic acid (HY-30215). This product is intended for research and analytical applications. (S)-Leucic acid is a metabolite of Leucine. (S)-Leucic acid has anabolic effects, particularly promoting muscle protein synthesis. (S)-Leucic acid can be used in the diagnosis of pregnancy loss .

HY-167917

Conjugated linoleic acid	Drug Isomer	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Conjugated linoleic acid is a group of isomers of Linoleic acid (HY-N0729) containing conjugated double bonds. Conjugated linoleic acid is mainly derived from dairy products and ruminant meats. Conjugated linoleic acid exhibits various activities such as anti-carcinogenicity, immunomodulation, weight loss promotion, reduction of muscle damage, and alleviation of inflammatory responses. Conjugated linoleic acid can be used as a food additive .

HY-150270

NP-1815-PX	Prostaglandin Receptor P2X Receptor NOD-like Receptor (NLR) Caspase Interleukin Related	Neurological Disease Inflammation/Immunology
NP-1815-PX is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC₅₀ of 0.26 μM against human P2X4 receptors. NP-1815-PX specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX is used in studies related to asthma and inflammatory bowel disease (colitis) .

HY-177971

Braxlosiran	Antibody-Oligonucleotide Conjugates (AOCs)	Neurological Disease
Braxlosiran, one of the components of the AOC Delpacibart braxlosiran (HY-177566), is composed of a siRNA targeting DUX4 (dual homologous box protein) and SMCC linker (HY-42360). Abnormal expression of the DUX4 protein leads to changes in gene expression in muscle cells, and these changes are associated with the loss of muscle function in facioscapulohumeral muscular dystrophy (FSHD) .

HY-N6609

Magnocurarine	nAChR	Others
Magnocurarine is a neuromuscular junction blocker that inhibits muscle contraction by functionally blocking signal transmission without directly damaging nerve or muscle tissues. In frog, mouse and rabbit models, Magnocurarine exerts a dose-dependent paralytic effect, which progresses gradually from limb weakness and loss of righting reflex to respiratory depression and even cardiac arrest. Although high doses cause complete cessation of movement, Magnocurarine does not affect the spinal multineuronal reflex in frogs. Magnocurarine exhibits biological activity similar to that of tubocurarine (HY-125901) in various animal models .

HY-W127851

CLA Cypridina luciferin analog	Biochemical Assay Reagents	Others Cancer
CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.

HY-138576

IDO1-IN-26	Indoleamine 2,3-Dioxygenase (IDO)	Metabolic Disease
IDO1-IN-26 (N-(2-Benzo[1,3]dioxol-5-yl-ethyl)-2-(4-methyl-benzyl)-succinamic acid SA) is a IDO1 inhibitor that can be used for the study of sarcopenia or age-related muscle loss .

HY-18102BS

GLPG0492-13C,d3 racemate	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
GLPG0492- ¹³C,d₃ racemate is ¹³C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

HY-121670

Ambenoxan	Others	Neurological Disease
Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.

HY-121670A

Ambenoxan hydrochloride	Adrenergic Receptor	Neurological Disease
Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.

HY-182773

MC4R Antagonist-1	Melanocortin Receptor	Metabolic Disease
MC4R Antagonist-1 (compound 1) is an MC4R-selective antagonist (IC₅₀<10 nM). MC4R Antagonist-1 can be used for the research of cachexia, anorexia, anorexia nervosa, involuntary weight loss, failure to thrive, sarcopenia, muscle wasting, muscle weakness, frailty, osteoporosis .

HY-B1562D

(S)-Bopindolol	Adrenergic Receptor	Metabolic Disease
(S)-Bopindolol is a β-adrenergic receptor blocker that can be used to prevent, inhibit, can be used to reduce muscle mass and/or functional loss and/or decreased bone density caused by weight loss. (S)-Bopindolol can protect the myocardium and/or cardiac function, or prevent low blood pressure and/or increased heart rate during weight loss .

HY-183005

ActRIIB-IN-1	TGF-β Receptor	Inflammation/Immunology Cancer
ActRIIB-IN-1, 7-azaindole compound is an orally active activin type II receptor B (ActRIIB) inhibitor with an IC₅₀ of 1.8 nM. ActRIIB-IN-1 can alleviate weight loss, muscle atrophy and decreased muscle strength caused by tumor cachexia, as well as improve appetite. ActRIIB-IN-1 can be used for the research of cancer cachexia .

HY-N6609B

Magnocurarine chloride	nAChR	Cardiovascular Disease
Magnocurarine chloride is a neuromuscular junction blocker that inhibits muscle contraction by functionally blocking signal transmission without directly damaging nerve or muscle tissues. In frog, mouse and rabbit models, Magnocurarine chloride exerts a dose-dependent paralytic effect, which progresses gradually from limb weakness and loss of righting reflex to respiratory depression and even cardiac arrest. Although high doses cause complete cessation of movement, Magnocurarine chloride does not affect the spinal multineuronal reflex in frogs. Magnocurarine chloride exhibits biological activity similar to that of tubocurarine (HY-125901) in various animal models .

Cat. No.	Product Name	Type

HY-W127851

CLA Cypridina luciferin analog	Biochemical Assay Reagents
CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.

CLA

Cypridina luciferin analog

Biochemical Assay Reagents

CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99355

Bimagrumab 3 Publications Verification Anti-ACVR2B Reference Antibody; BYM338	TGF-β Receptor	Metabolic Disease
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with K_Ds of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1993

5-Methyl-7-methoxyisoflavone 3 Publications Verification	Flavonoids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Isoflavones Source Classification	Cytochrome P450 NF-κB
5-Methyl-7-methoxyisoflavone is an orally active anti-oxidant with remyelinating activity. 5-Methyl-7-methoxyisoflavone inhibits the enzyme aromatase, interfering with the normal metabolic pathways of testosterone. 5-Methyl-7-methoxyisoflavone is a non-steroidal anabolic isoflavone, used as a anabolic agent. 5-Methyl-7-methoxyisoflavone shows better potency increasing muscle mass and endurance than Ipriflavone (HY-N0094). 5-Methyl-7-methoxyisoflavone can be used for fat loss besides the maintenance of low cholesterol level and strengthen bones. 5-Methyl-7-methoxyisoflavone is the inhibitor for NF-κB .

HY-30215

(S)-Leucic acid	Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Other Diseases Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
(S)-Leucic acid is a metabolite of Leucine. (S)-Leucic acid has anabolic effects, particularly promoting muscle protein synthesis. (S)-Leucic acid can be used in the diagnosis of pregnancy loss .

HY-N6609

Magnocurarine	Alkaloids Structural Classification Classification of Application Fields Other Diseases Phenols Polyphenols Plants Cissampelos pareira Isoquinoline Alkaloids Menispermaceae Disease Research Fields Source Classification	nAChR
Magnocurarine is a neuromuscular junction blocker that inhibits muscle contraction by functionally blocking signal transmission without directly damaging nerve or muscle tissues. In frog, mouse and rabbit models, Magnocurarine exerts a dose-dependent paralytic effect, which progresses gradually from limb weakness and loss of righting reflex to respiratory depression and even cardiac arrest. Although high doses cause complete cessation of movement, Magnocurarine does not affect the spinal multineuronal reflex in frogs. Magnocurarine exhibits biological activity similar to that of tubocurarine (HY-125901) in various animal models .

HY-N6609B

Magnocurarine chloride	Structural Classification Alkaloids Tiliacora racemosa Colebr. Plants Isoquinoline Alkaloids Menispermaceae Source Classification	nAChR
Magnocurarine chloride is a neuromuscular junction blocker that inhibits muscle contraction by functionally blocking signal transmission without directly damaging nerve or muscle tissues. In frog, mouse and rabbit models, Magnocurarine chloride exerts a dose-dependent paralytic effect, which progresses gradually from limb weakness and loss of righting reflex to respiratory depression and even cardiac arrest. Although high doses cause complete cessation of movement, Magnocurarine chloride does not affect the spinal multineuronal reflex in frogs. Magnocurarine chloride exhibits biological activity similar to that of tubocurarine (HY-125901) in various animal models .

Cat. No.	Product Name	Chemical Structure

HY-18102BS

GLPG0492-13C,d3 racemate
GLPG0492- ¹³C,d₃ racemate is ¹³C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

GLPG0492-13C,d3 racemate

GLPG0492- ¹³C,d₃ racemate is ¹³C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

Cat. No.	Product Name		Classification

HY-177971

Braxlosiran		siRNAs
Braxlosiran, one of the components of the AOC Delpacibart braxlosiran (HY-177566), is composed of a siRNA targeting DUX4 (dual homologous box protein) and SMCC linker (HY-42360). Abnormal expression of the DUX4 protein leads to changes in gene expression in muscle cells, and these changes are associated with the loss of muscle function in facioscapulohumeral muscular dystrophy (FSHD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

muscle loss

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products